Relates to access to appropriate drugs at reasonable prices, formulary exceptions, standing prior authorizations and external appeals; to access to retail pharmacies, prescription synchronization, limits on patient drug costs, explanations of benefits and rebates; to prescription drug synchronization; to pharmacy benefit management; and to limits on copayments and drug substitutions.

New York Assembly Bill A05282 aims to make prescription drugs more affordable and accessible. It seeks to ensure that patients can obtain necessary medications at reasonable prices by allowing exceptions to insurance formularies and establishing standing prior authorizations and external appeals processes. The bill also focuses on improving access to retail pharmacies and supports prescription synchronization, which aligns medication refills to a single date, reducing the number of trips patients need to make. Additionally, it proposes limits on patient drug costs, mandates clear explanations of benefits and rebates, and imposes restrictions on copayments and drug substitutions. The bill has been referred to the Assembly Insurance Committee and is currently pending. ([legiscan.com](https://legiscan.com/NY/bill/A05282/2025?utm_source=openai))

While specific media coverage on Assembly Bill A05282 is limited, similar legislative efforts in other states have been met with support from patient advocacy groups and healthcare professionals. These stakeholders often praise such initiatives for enhancing medication affordability and patient access to necessary treatments. The bill's focus on prescription synchronization and clear communication of benefits aligns with ongoing efforts to improve healthcare delivery and patient satisfaction.

There is no significant negative media coverage or opposition reported regarding Assembly Bill A05282. However, similar legislative proposals in other regions have faced challenges related to implementation complexities and potential resistance from pharmaceutical companies concerned about profit margins. Some critics argue that such measures could lead to increased administrative burdens and costs for healthcare providers.